Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD2693 in Healthy and Overweight Subjects
NCT04142424Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2019
- Primary completion
- Nov 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD2693 in Nonalcoholic steatohepatitis (NASH) (9 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of subjects experiencing adverse events and serious adverse events at 16 weeks. Started Oct 2019; status: completed.
02
Drugs
AZD2693
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04142424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142424.